Posts

Posted on

Community Health Systems Invests for Strategic Growth in Ambulatory Surgery Centers

Community Health Systems Invests for Strategic Growth in Ambulatory Surgery Centers

FRANKLIN, Tenn.–(BUSINESS WIRE)–
Community Health Systems, Inc. (NYSE: CYH) is steadily growing its network of ambulatory surgery centers (ASC) offering same-day surgical care. In the first part of 2026 alone, subsidiaries opened de novo centers in Birmingham and Foley, Alabama, and acquired a majority ownership interest in a center in Anchorage, Alaska, increasing the count to 36 affiliated ASCs.

The ASC count will soon grow to 37, as a subsidiary of the Company recently signed definitive agreements to acquire a majority ownership interest in Surgical Clinic Solutions, LLC dba Surgical Institute of Alabama (SIA) in Vestavia, Alabama.

The freestanding SIA performs more than 8,000 cases per year and is the largest multi-specialty surgery center in Alabama. Located in a Birmingham suburb, SIA has six operating rooms, two procedure rooms, nine pre-op and nine post-acute beds. Surgical specialists practicing at SIA deliver neurospine, orthospine, orthopedics, total joint reconstruction, general, urology and pain management procedures.

“Our targeted investments in ambulatory surgery centers extend our ability to provide care in the most advantageous way for our patients,” said Kevin Hammons, Chief Executive Officer of Community Health Systems, Inc. “By offering additional services through these outpatient settings, we are driving growth for our health systems, delivering quality care and excellent outcomes, and optimizing the surgical experience for both our physician partners and their patients.”

The SIA transaction is expected to close in the second quarter of 2026, subject to customary closing conditions. Terms of the transaction remain confidential.

When the SIA transaction is complete, CHS affiliate Grandview Health in Birmingham, Alabama, will have four ambulatory surgery centers offering the convenience of outpatient surgical services. Birmingham Musculoskeletal Institute at Grandview Health, which opened in April 2026, joined Grandview Urology Surgery Center and Grandview Endoscopy Center on the campus of Grandview Medical Center.

CHS affiliate Baldwin Health in Foley, Alabama, opened its de novo Specialty Surgery Center in February 2026. The center delivers orthopedic surgery, gastroenterological surgery, pain management and colonoscopy procedures. Baldwin Health has also completed a $154 million expansion, adding a five-story, nearly 200,000-square foot tower that doubled intensive care beds, added inpatient beds, an enhanced women’s and children’s unit with a Level II NICU, new operating suites and surgical technology to increase capacity for delivering care in coastal Alabama, one of the country’s fastest growing communities.

Effective April 1, 2026, a subsidiary of the Company completed the acquisition of a majority ownership interest in South Anchorage Surgery Center in Anchorage, Alaska. The center specializes in gastrointestinal and interventional pain procedures and adds surgical capacity for CHS affiliate Mat-Su Regional Medical Center in Palmer, Alaska.

About Community Health Systems

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 33 distinct markets across 13 states. The Company’s subsidiaries own or lease 64 affiliated hospitals with more than 9,000 beds and operate more than 900 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.

Media Contact:

Tomi Galin

Executive Vice President, Corporate Communications, Marketing and Public Affairs

(615) 628-6607

Investor Contacts:

Kevin J. Hammons

Chief Executive Officer

(615) 465-7000

Anton Hie

Vice President – Investor Relations

(615) 465-7012

KEYWORDS: Tennessee Alabama Alaska United States North America

INDUSTRY KEYWORDS: Practice Management Nursing Managed Care Surgery General Health Health Hospitals Other Health

MEDIA:

Logo
Logo
Posted on

Energy Focus, Inc. Announces Strategic Entry into Japan’s Energy Storage Market

Energy Focus, Inc. Announces Strategic Entry into Japan’s Energy Storage Market

SOLON, Ohio–(BUSINESS WIRE)–
Energy Focus, Inc. (NASDAQ: EFOI), a leader in sustainable, energy-efficient light-emitting diode (“LED”) lighting and energy infrastructure solutions, today announced a joint investment with Japan’s Meihodo Co., Ltd. and Euka Power Japan Co., Ltd. in an energy storage power plant located in Asakura, Fukuoka, Japan. Holding a 35% stake, EFOI will play a lead role in battery procurement and related energy management functions, positioning the Company to participate in the power regulation market, one of the most valuable segments in the global energy industry. The project has already received a grid application response from Kyushu Electric Power and is expected to reach Commercial Operation Date (“COD”) in the second half of 2026. This milestone will translate into visible revenue and cash flow, serving as the launchpad for EFOI’s “energy platform” strategy.

Investment Highlights & Strategic Transformation

  • Financial Targets: With a total project investment of approximately 500 million JPY (approximately $3.13 million), of which the Company’s 35% share represents approximately 175 million JPY (approximately $1.10 million), the project aims for an Internal Rate of Return (“IRR”) exceeding 35%.
  • Revenue Streams: By leveraging Japan’s balancing market, capacity market, and real-time arbitrage mechanisms, the project is designed to generate revenue from multiple power market participation opportunities.
  • Business Pivot: This highly replicable and scalable model facilitates EFOI’s transition from a traditional energy products company into an asset-and-data-driven “Energy-as-a-Service” (“EaaS”) platform.

Market Positioning in Japan

As one of the world’s most critical markets for energy transition, Japan offers high electricity prices, stable demand, and robust policy support. This move is more than a single project investment; it is the core node for EFOI to establish a regional energy network and Virtual Power Plant (“VPP”) capabilities. Utilizing its proprietary energy storage technology, Energy Management Systems (“EMS”), and power aggregation capabilities, the company is set to fully penetrate the power trading and energy services market, significantly raising its earnings ceiling.

Future Outlook and Valuation

EFOI intends to use this project as a springboard to accelerate expansion across Japan and the broader Asia-Pacific region. Over the next five years, the company is targeting over 1GW in energy storage and energy product sales opportunities, subject to market conditions and successful project execution, tapping into a potential multi-hundred-million-dollar market. As asset scale and profitability rise, EFOI is poised to reshape its valuation logic, emerging as a high-growth energy technology platform of significant interest to capital markets.

“This investment marks a meaningful milestone in Energy Focus’ evolution and reflects our confidence in the long-term opportunity within Japan’s energy storage and power regulation markets,” said Chiao-Chieh (Jay) Huang, Chief Executive Officer of Energy Focus. “We are particularly excited about the combination of attractive project-level returns and the strategic platform it creates for future expansion. This project not only demonstrates the strength of our technology and partners, but also establishes a scalable model that we believe can be replicated across Japan and the broader Asia-Pacific region. As we build out this energy platform, we see a clear path toward recurring revenue, stronger cash flow visibility, and significant long-term value creation for our shareholders.”

About Energy Focus

Energy Focus is a leader in energy-efficient LED lighting and energy infrastructure solutions. As the creator of the first flicker-free LED lamps, Energy Focus develops high quality LED lighting products and controls that provide extensive energy and maintenance savings, as well as aesthetics, safety, health and sustainability benefits over conventional lighting. Energy Focus is headquartered in Solon, Ohio. For more information, visit our website at www.energyfocus.com. The Company routinely posts important updates on its website.

Forward-Looking Statements:

This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Among the specific forward-looking statements in this release are the Company’s projected internal rate of return for the Asakura project, the Company’s five-year target of over 1GW in energy storage and energy product sales, and the characterization of the associated market opportunity as potentially worth several hundred million dollars. Such projections are subject to significant additional risks and uncertainties, including regulatory approvals in Japan, currency fluctuations, the performance of joint venture partners, energy market conditions, and the availability of project financing, and actual results may differ materially. The Company encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.

Investor Contact:

Chiao Chieh (Jay) Huang

Chief Executive Officer

(800) 327-7877

KEYWORDS: Ohio United States Japan North America Asia Pacific

INDUSTRY KEYWORDS: Hardware IOT (Internet of Things) Alternative Energy Green Technology Energy Sustainability Manufacturing Technology Batteries Environment Other Manufacturing Other Technology Software Other Energy Utilities Engineering

MEDIA:

Logo
Logo
Posted on

AlphaTON Capital Relaunches as Alpha Compute Corp. to Reflect Its Growing AI Compute Business

New Ticker NASDAQ: “ALP” for Alpha Represents The Company’s Strategic Focus on Scalable, AI Confidential Computing Infrastructure, leaning into its success with AI Confidential Computing for Telegram and other Clients

Road Town, Tortola, British Virgin Islands, April 20, 2026 (GLOBE NEWSWIRE) — Alpha Compute Corp. (NASDAQ: ALP) (formerly AlphaTON Capital Corp., NASDAQ: ATON) (“Alpha Compute” or the “Company”), a technology leader in AI GPU-as-a-service (GPUaaS) and AI Confidential Compute, today announced that it has rebranded from AlphaTON Capital Corp. to Alpha Compute Corp., with its common shares trading under the new ticker symbol “ALP” on the Nasdaq Stock Market. The rebrand reflects the Company’s accelerating strategic growth and market demand for scalable AI compute infrastructure, with privacy-preserving confidential computing at its core.

Rebranding to Reflect the Company’s True Mission

The name Alpha Compute signals the Company’s intent to lead the global race to build the AI infrastructure of the future. As artificial intelligence reshapes how the world stores, processes, and monetizes data, the demand for sovereign, privacy-first compute has become structural. Alpha Compute is purpose-built for this moment.

“This rebrand is not cosmetic, it is structural,” said Brittany Kaiser, CEO of Alpha Compute Corp. “From the moment I wrote Targeted and first testified before Congress and Parliament about data rights, my mission has been to ensure that the future of technology is built on privacy by design, not just policy and promises. Alpha Compute is the culmination of that mission: a publicly traded infrastructure company providing the world’s most sensitive AI workloads with compute they can trust. We are entering the fastest-growing industry in history, and we intend to lead it.”

The Fastest-Growing Global Industry

The global AI market, valued at approximately $390 billion in 2025, is projected to reach $3.5 trillion by 2033 (Grandview Research, 2025), growing at a compound annual growth rate of more than 30%. Global AI spending is expected to surpass $2.52 trillion in 2026 alone, a 44% increase year over year (Gartner Group, 2025). The AI chip market sales were $200 billion in 2025, with the NVIDIA Blackwell architecture, the same generation powering Alpha Compute’s infrastructure, driving the majority of that growth. NVIDIA’s own fiscal year 2026 revenues reached $215.9 billion, up 65% year over year (source: Nvidia press release), underscoring the relentless demand for advanced GPU compute.

Over 70% of Enterprise AI Workloads will Require AI Confidential Computing

Within this market, confidential computing represents one of the highest-growth and highest-value segments. Enterprises in healthcare, financial services, government, and defense represent over $2 trillion in combined annual IT spending (Gartner), and cannot rely on standard cloud infrastructure for their most sensitive AI workloads. Alpha Compute solves this problem with infrastructure that is private by encrypted architecture, not by promise. 

The convergence trend represents the significant market signal. Operationally, the key factor is that confidential computing is transitioning from a standalone market to the embedded security layer within the broader Secure AI Cloud stack. By 2026, over 70% of enterprise AI workloads will incorporate sensitive data, thereby accelerating the demand for secure AI infrastructure (Fortune Business Insights). Consequently, the addressable opportunity is more accurately defined as a segment of the cloud AI market, specifically where stringent security and data sovereignty mandates restrict workload migration.

Regulatory pressure has become a compelling catalyst. The escalating use of AI within enterprises is driving major concerns around data sovereignty, as current infrastructure designs struggle to provide the necessary guarantees for regulated or sensitive workloads. As reported by Computer Weekly, the confluence of the EU AI Act enforcement in 2026, the updated FedRAMP 20x requirements, and various national data residency laws is creating a mandatory, rather than merely opportunistic, procurement cycle.

What Alpha Compute Delivers

Under its new identity, Alpha Compute will operate as an integrated AI compute infrastructure company, providing:

  1. Confidential AI Compute via hardware-enforced trusted execution environments (TEEs) and NVIDIA Blackwell-generation GPU clusters (B200 and B300 architectures), ensuring data remains encrypted in use, in transit, and at rest.
  2. Sovereign AI Infrastructure enabling enterprise clients, government entities, and regulated industries to run AI workloads without surrendering data sovereignty to hyperscale cloud providers.
  3. Scalable GPU Deployment through Alpha Compute and its subsidiaries, with operational infrastructure backed by binding agreements for the deployment of over 1,000 Blackwell-generation GPUs.
  4. Privacy-Native AI Ecosystems supporting partners including Telegram, Midnight, Animoca Brands, and others building next-generation secure applications for the world’s most sensitive data and users.

“Our journey to this pivotal moment has been defined by the comprehensive infrastructure buildout over the last six months—specifically, the development of core firmware for Telegram’s Cocoon AI launch and securing hardware-level encryption on B300s. Our operations are expansive, covering GPU procurement, data center colocation, confidential computing architecture, and robust partner ecosystem development. Alpha Compute stands as a specialized, scalable AI compute company, poised to capitalize on a generational market shift by offering reliable independence and protecting your data from hyperscalers’ increasing encroachment.” – Enzo Villani, Executive Chairman and CIO, Alpha Compute Corp.

Strategic Continuity

The rebrand does not alter the Company’s corporate structure, legal domicile, or existing contractual obligations. All existing agreements, including the Company’s binding lease for NVIDIA B200s and the purchase of B300 GPU servers, the $43 million AI infrastructure and financing partnership with Vertical Data Inc., the GAMEE acquisition, infrastructure support for Telegram’s Cocoon AI, and the Company’s digital asset holdings, remain in full effect under the Alpha Compute Corp. entity. The Company’s existing shareholders are not required to take any action in connection with the ticker or name change.

Investors and analysts should update their records to reflect the new ticker symbol ALP effective today on the Nasdaq Stock Market.

Board of Directors and Executive Officers

  • Enzo Villani, Executive Chairman and Chief Investment Officer
  • Brittany Kaiser, Board Member and Chief Executive Officer, Governance & Nominating Committee Chair
  • Michael Terpin, Independent Board Member, Audit Committee, Corporate Governance Committee
  • F. Daniel Siciliano, Independent Director, Audit Committee Chair, Corporate Governance Committee Chair
  • Wes Levitt, Chief Financial Officer
  • Yury Mitin, Chief Business Development Officer

About Alpha Compute Corp.

Alpha Compute Corp. (NASDAQ: ALP), formerly AlphaTON Capital Corp. (NASDAQ: ATON), owns and operates AI infrastructure powered by confidential compute and hardware-level encryption. Alpha Compute’s GPU assets deliver privacy-preserving computation to partners and applications including Telegram, Animoca Brands, and Midnight Network. 
Learn more at alphacompute.ai.

Forward-Looking Statements

All statements in this press release, other than statements of historical facts, including without limitation, statements regarding the Company’s business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words “believe,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “plans,” “potential,” “continues,” or similar expressions or variations on such expressions are forward-looking statements. Forward-looking statements include statements concerning, among other things, the Company’s projections for its AI infrastructure expansion deployment; the Company’s expectations that its partnerships will create additional revenue streams and vertically integrate into the Company’s Confidential Compute AI Infrastructure; the Company’s belief that the assets it is building will drive significant long-term value; and other statements that are not historical fact. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the timing, progress and results of the Company’s strategic initiatives, the Company’s reliance on third parties, the risk that the Company may not secure additional financing or TON, the uncertainty of the Company’s investment in TON, the uncertainty around the Company’s legacy business, the operational strategy of the Company, the Company’s executive management team, risks from Telegram’s platform and ecosystem, the potential impact of markets and other general economic conditions, and other factors set forth in “Item 3 – Key Information-Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2025 and included in the Company’s Form 6-Ks filed with the Securities and Exchange Commission on September 3, 2025 and January 13, 2026. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Investor Relations:


Alpha Compute Corp.
[email protected]
(203) 682-8200

Media Inquiries:
Richard Laermer
RLM PR
[email protected]
(212) 741-5106 X 216



Richard Laermer
AlphaCompute(at)rlmpr.com

Posted on

Investcorp Credit Management BDC, Inc. Engages Financial Advisor to Assist in Ongoing Review of Strategic Alternatives

Investcorp Credit Management BDC, Inc. Engages Financial Advisor to Assist in Ongoing Review of Strategic Alternatives

NEW YORK–(BUSINESS WIRE)–
Investcorp Credit Management BDC, Inc. (NASDAQ: ICMB) (“ICMB” or the “Company”) today announced that it has engaged Houlihan Lokey, a leading independent investment bank, as its financial advisor to assist the Special Committee of Independent Directors in its ongoing review of strategic alternatives.

As previously announced, the Special Committee is evaluating a broad range of strategic, financial and business configuration options for the Company.

ICMB has not set a timetable for the conclusion of its review and has not made any decisions at this time. There can be no assurance that the review will result in the completion of any specific transaction or outcome. The Company does not intend to comment further with respect to this review unless or until its Board of Directors has approved a definitive course of action, the review process has concluded, or it is determined that other disclosure is appropriate.

About Investcorp Credit Management BDC, Inc.

The Company is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments by targeting investment opportunities with favorable risk-adjusted returns. The Company seeks to invest primarily in middle-market companies that have annual revenues of at least $50 million and earnings before interest, taxes, depreciation, and amortization of at least $15 million. The Company’s investment activities are managed by its investment adviser, CM Investment Partners LLC (“CMIP”). Investcorp Credit Management US LLC (“Investcorp”), a subsidiary of Investcorp Bank B.S.C., controls CMIP. To learn more about Investcorp Credit Management BDC, Inc., please visit www.icmbdc.com.

Forward Looking Statement

Statements included in this press release may contain “forward-looking statements,” which relate to future performance, operating results, events, financial condition and/or exploration of strategic alternatives. Words such as “anticipates,” “expects,” “intends,” “plans,” “will,” “may,” “continue,” “believes,” “seeks,” “estimates,” “would,” “could,” “should,” “targets,” “projects,” and variations of these words and similar expressions are intended to identify forward-looking statements. Any forward-looking statements, including statements other than statements of historical facts, included in this press release are based upon current expectations, are inherently uncertain, and involve a number of assumptions and substantial risks and uncertainties, many of which are difficult to predict and are generally beyond the Company’s control.

Investors are cautioned not to place undue reliance on these forward-looking statements. Any such statements are likely to be affected by other unknowable future events and conditions, which the Company may or may not have considered, including, without limitation, (i) the ability of the Company to identify and complete any strategic transaction or other course of action; (ii) the timing and outcome of the strategic review process; (iii) changes in base interest rates; (iv) the effects of significant market volatility on our business, our portfolio companies, our industry and the global economy; and (v) other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Accordingly, such statements cannot be guarantees or assurances of any aspect of future performance or events. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors and risks. More information on these risks and other potential factors that could affect actual events and the Company’s performance and financial results, including important factors that could cause actual results to differ materially from plans, estimates or expectations included, is or will be included in the Company’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s 2025 Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. All forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Investcorp Credit Management BDC, Inc.

Investor Relations

Email: [email protected]

Phone: (212) 703-1154

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Posted on

Intapp and DCM Insights expand Activator partnership, adding Intapp Celeste agents to accelerate business development in professional and financial services firms

Intapp and DCM Insights expand Activator partnership, adding Intapp Celeste agents to accelerate business development in professional and financial services firms

DCMi’s Activator research identifies what the best partners do differently; Intapp Celeste gives them the intelligence to act on it faster.

PALO ALTO, Calif.–(BUSINESS WIRE)–
Intapp (NASDAQ: INTA), the leading governed AI platform for professional firms in highly regulated industries, and DCM Insights (DCMi) announced the next phase of their strategic partnership. Building on an earlier research sponsorship and the integration of DCMi’s Activator research into Intapp DealCloud, the two firms are deepening their collaboration to address one of the most persistent challenges facing professional services partners: turning new business development behaviors into durable habits—through Activator playbooks delivered by Intapp Celeste.

DCMi’s Activator programs are built on research published by Harvard Business Review into how the best partners develop business and what separates them from the rest. Across more than 100 of the world’s leading professional and financial services firms, those programs are driving structured, measurable behavior change. Intapp Celeste, Intapp’s agentic AI platform for professional firms, surfaces relationship signals, identifies client engagement opportunities, and delivers prioritized next-best actions directly to partners. Together, the two platforms go further: DCMi’s Activator research informs the behaviors that drive growth, and Intapp Celeste scales those behaviors through Activator playbooks built directly into the platform — purpose-built agentic workflows that put the right intelligence in front of partners at the right moment.

“Building a governed AI platform that meets the requirements of the world’s leading professional and financial services firms means partnering with the best in every category — companies like Microsoft, Anthropic, and Harvey,” said John Hall, Chairman and CEO of Intapp. “It also means being honest about where technology adoption actually fails. Partners don’t resist new tools because the technology isn’t good enough. They resist when the tools don’t account for how they actually work, how their clients’ buying behavior is changing, and what the most effective partners are doing differently. DCMi has spent years answering those questions through rigorous research. That’s why this partnership matters.”

“When it comes to making new business development behaviors stick, we find that the challenge isn’t a lack of partner willingness, it’s a lack of time. Only when new behaviors are practiced and honed will they become habits and routines. But this is hard given the many competing demands for a partner’s time. Partners are doer-sellers, not full-time sellers,” said Matt Dixon, Founding Partner of DCMi and co-author of The Activator Advantage: What Today’s Rainmakers Do Differently. “This is what’s so exciting about Intapp’s new Celeste AI platform. Having Celeste’s Activator agents working in the background for a partner is like having a ‘personal business development assistant’—spotting movement in their networks, identifying opportunities to engage new clients and surfacing next-best opportunities for cross-selling and collaboration—so that when they do find time for business development, they’re served up a highly actionable punch list of activities to pursue. We’re honored to be part of the team bringing this exciting new platform to the market.”

About DCM Insights

DCMi is a Washington, DC-based firm that provides business development behavior change programs for partners and associates in professional and financial services firms. The company’s programs are based on its proprietary Activator research which was featured in Harvard Business Review and in the book, The Activator Advantage: What Today’s Rainmakers Do Differently, published by Harvard Business Review Press in 2025. More than 100 of the world’s leading firms use DCMi’s Activator behavior change program, including nine of the AmLaw 15, four of the five Magic Circle law firms, all of the Big 4, and four of the top five executive search firms. The company was ranked #112 in the 2025 Inc. 5000 list of America’s fastest-growing private companies.

About Intapp

Intapp (NASDAQ: INTA) is the governed AI platform for professional firms in highly regulated industries. Intapp’s vertically tailored agentic solutions are built for the specialized workflows, complex relationship networks, and professional compliance requirements of accounting, consulting, investment banking, law, private capital, and real assets firms. By applying Firm AI to core processes and data, Intapp helps partners, dealmakers, and advisors drive firm growth, manage compliance, and improve profitability. Learn why the world’s top firms trust Intapp’s industry-specific enterprise solutions at intapp.com.

Jen Mara

919-345-1668

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Finance Consulting Artificial Intelligence Data Management Professional Services Technology Fintech

MEDIA:

Logo
Logo
Posted on

Conduent Named a Leader in Everest Group’s 2026 Healthcare Payer Intelligent Operations PEAK Matrix® Assessment

Conduent Named a Leader in Everest Group’s 2026 Healthcare Payer Intelligent Operations PEAK Matrix® Assessment

Recognition highlights Conduent’s platform-led delivery, embedded GenAI, and ecosystem partnerships that drive measurable payer outcomes

FLORHAM PARK, N.J.–(BUSINESS WIRE)–Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced that Everest Group has recognized Conduent as a Leader in its Healthcare Payer Intelligent Operations PEAK Matrix® Assessment 2026. The assessment evaluates providers serving U.S. health plans across back-office and technology-enabled operations, measuring both market impact and vision & capability.

Everest Group notes that Leaders demonstrate investment in technology, a shift toward embedded, end-to-end workflow automation, and a centralized AI enablement strategy.

Conduent Strengths

In its analysis, Everest Group highlighted Conduent’s:

  • Single-instance core administrative platform, Health Solutions Plus (HSP), supporting major payer lines of business
  • Embedded AI across payer operations, including document classification, fraud detection, claims summarization and real-time agent guidance
  • High client satisfaction, with clients citing strong account management and proactive issue resolution
  • Ecosystem partnerships, including workwith Microsoft Azure to advance its AI capabilities and solutions.

“The payer market is increasingly adopting platform-led intelligent operations that operationalize AI, automation, and governance-backed execution to address growing operational complexity, while still delivering faster service at lower administrative cost,” said Vivek Kumar, Practice Director, Everest Group. “Conduent is responding to these evolving market needs with investments in its core administrative platform (HSP), supported by a built-in CRM, and preconfigured Medicare Advantage templates, reinforcing its positioning as a Leader in Everest Group’s Healthcare Payer Intelligent Operations PEAK Matrix® Assessment 2026.”

“Sustained margin pressure from rising medical costs and evolving regulations is accelerating the shift to AI‑enabled, platform‑based operating models across healthcare payers,” said Kimberly Marshall, Chief Commercial Officer of Commercial Solutions at Conduent. “Conduent helps clients meet these challenges through solutions like the HSP payer suite, an all‑in‑one, highly automated platform designed to reduce costs, modernize technology stacks, and support end‑to‑end operations from claims and enrollment to CRM and member and provider engagement.”

To read a custom version of the report, visit: Everest Group Healthcare Payer Intelligent Operations PEAK Matrix Assessment 2026

Everest Group Disclaimer

Licensed extracts taken from Everest Group’s PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.

About Conduent

Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 51,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $80 billion in government payments annually, enabling approximately 2.0 billion customer service interactions annually, empowering millions of employees through HR services every year and processing over 14 million tolling transactions every day. Learn more at www.conduent.com.

Note:To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit https://x.com/Conduent, http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent.

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contacts:

Sean Collins, Conduent, +1-310-497-9205, [email protected]

Investor Relations Contact:

Joshua Overholt, Conduent, [email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Technology Payments Health Technology Professional Services Health Insurance Software Data Analytics Health Data Management Artificial Intelligence

MEDIA:

Logo
Logo
Posted on

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models

Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance

Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly evolving TROP2 ADC class expected to reach ~$12B by 2033

1

TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research (AACR) Annual Meeting 2026. Access the poster here.

Unlike current TROP2-targeting ADCs that use Topoisomerase I Inhibitor (Inh.) payloads, AKTX-101 has the potential to address resistance to Topoisomerase I Inh. ADCs and contribute to durable anti-tumor efficacy due to the payload’s unique cytotoxic and immune-activating mechanisms of action.

The preclinical data compares the performance of AKTX-101 versus TROP2 ADCs with Topoisomerase I Inh. payloads in the killing of different cancer types driven by different cancer genes (oncogenes). AKTX-101’s ability to kill cancer cells at lower concentrations vs. TROP2 ADCs using Topoisomerase I Inh. payloads suggests that AKTX-101 is a more potent drug.

The preclinical data was published recently as an abstract in Cancer Research, an AACR journal.

Here, AKTX-101 demonstrated greater potency and/or greater maximum cancer cell killing relative to TROP2 ADC Topoisomerase I Inh. payloads in cancers of the bladder, lung and breast. AKTX-101 demonstrated sub-nanomolar potency in all bladder cancer lines tested, a key tumor in which first-in-human clinical trials for AKTX-101 are planned.

AKTX-101 also demonstrated sub-nanomolar potency in several non-small cell lung cancer cell lines driven by EGFR, BRAF, and SMARCA4, as well as potent cell killing in HER2 breast cancer cell lines with inherent resistance to Topoisomerase I Inh. ADCs such as trastuzumab deruxtecan (ENHERTU™).

“These data represent a significant step forward for our lead program, AKTX-101, and reinforce our belief that a differentiated ADC payload with multiple mechanisms of action has the potential to meaningfully improve outcomes for patients with TROP2-expressing cancers,” commented Satyajit K. Mitra, Ph.D., Head of Oncology Research and Development at Akari Therapeutics. “We are seeing preclinical superior AKTX-101 potency and activity as compared to TROP2 ADCs using Topoisomerase I inhibitor payloads in bladder, lung, and breast cancer models. Together, these findings show that AKTX-101 has strong potential for targeting a broad range of cancer tumors and sub-types with superior cytotoxicity than current TROP2 ADCs that use Topoisomerase I Inhibitor payloads.”

The TROP2 ADC class continues to emerge in terms of its potential, with revenue projections expected to reach ~$12B or greater by 2033 based on current and future entrants. Akari believes that AKTX-101, with its novel RNA splicing modulator payload, can grow this class further by addressing multiple solid tumors where TROP2 is overexpressed including bladder, lung, breast, pancreatic, head and neck, and others.

Key AKTX-101 Data Presented at AACR Highlights:

  • AKTX-101 demonstrated strong, single-agent anti-tumor activity across multiple models across bladder, lung, and breast cancers.
  • AKTX-101 demonstrated greater potency and cell killing compared to current TROP2 ADCs, including Topoisomerase I inhibitor-resistant tumor models, as well as standard-of-care chemotherapies and targeted therapies. Combination of AKTX-101 with anti-PD-1 therapy resulted in synergistic anti-tumor efficacy and tumor regressions within in vivo models, supporting future combinations with checkpoint inhibition to maximize tumor remissions rates.
  • Broad in vitro cytotoxicity was observed across a diverse panel of tumor models, including those with clinically oncogenic driver mutations including FGFR3, BRAF, EGFR, and SMARCA4.

Abizer Gaslightwala, CEO of Akari Therapeutics, added, “This data continues to add to the conviction and differentiation we have in our novel ADC payload PH1 targeting RNA splicing. We are focused on rapidly advancing AKTX-101 into the clinic, with IND-enabling studies underway and plans to submit an IND in the fourth quarter of 2026, followed by initiation of a Phase 1 study in the first quarter of 2027. Our team is executing against a clear development plan designed to efficiently translate these encouraging preclinical findings into clinical proof of concept.”

These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. Access the poster here.

¹ DataIntelo, TROP2-Targeted Therapies Market Report, 2026

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements 

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients, and the timing of the submission of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]



Posted on

Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026

PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com. 

Investor Relations:

Chris Ward

(609) 772-7736
[email protected]   

Media Contact:

Laurene Isip

(609) 208-8121
[email protected]

Integra LifeSciences Holdings Corporation



Posted on

ENvue Medical Announces 40th U.S. Hospital Customer with Addition of a Virginia Medical Center Affiliated with the Mayo Clinic Care Network

Regional hospital transitions feeding tube procedures from interventional radiology to bedside nursing care using the ENvue™ Navigation Platform

TYLER, Texas, April 20, 2026 (GLOBE NEWSWIRE) — ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced that a Virginia-based, 255-bed nonprofit regional medical center affiliated with the Mayo Clinic Care Network is now using the ENvue™ Navigation Platform. The hospital is now performing feeding tube placement through a nursing-led bedside model, transitioning procedures from interventional radiology to trained clinical staff at the point of care.

“The transition to a nursing-led bedside model reflects a growing focus on efficiency and patient-centered care across hospital systems,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “With ENvue, care teams can perform feeding tube placement at the bedside, shifting procedures from interventional radiology to trained nursing staff and supporting a more streamlined process that reduces reliance on resource-intensive departments while maintaining clinical precision.”

The agreement marks ENvue’s 40th U.S. hospital customer. The Virginia-based medical center, serving more than 300,000 people, expands ENvue’s presence across regional health systems.

“We’re seeing growing demand for technologies that bring greater visibility and consistency to feeding tube placement,” said Marc Waldman, Vice President of Commercial at ENvue Medical. “Hospitals are looking for solutions that can be implemented across care teams, and we believe that real-time visualization helps support more standardized practices throughout the hospital.”

The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure.

About ENvue Medical, Inc.

ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:

  • ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
  • ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
  • Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:

KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
[email protected]

Media Contact:

KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
[email protected]



Posted on

SAIC Awarded New $75.2M PRISM Task Order to Advance the Naval Air Systems Command’s Mission-Critical Aviation Systems

Contract modernizes and sustains the technology and infrastructure of Aircraft Armament Equipment (AAE), Support Equipment (SE), and Aerial Refueling System (ARS) integration for the MQ-25, building on SAIC’s 20-year partnership with the U.S. Navy

RESTON, Va., April 20, 2026 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC) has been awarded a new $75.2 million task order under the General Services Administration (GSA) Personnel and Readiness Infrastructure Support Management (PRISM) contract to provide critical support to the Naval Air Systems Command (NAVAIR). This contract expands on SAIC’s two decades of trusted collaboration with the Navy to advance critical equipment and systems needed by our warfighters.

SAIC will leverage predictive analytics and digital engineering tools to improve reliability, reduce downtime, and enhance the operational lifespan of AAE systems, which is vital to supporting global naval contingency operations. SAIC will provide engineering and sustainment services for NAVAIR’s SE, used to manage critical aviation systems and provide any troubleshooting support in real time. Additionally, SAIC will drive the development and integration of the Navy’s ARS efforts for the MQ-25 Stingray — an unmanned platform designed to extend the operational range of carrier air wings.

“For more than 20 years, we have worked hand in hand with the Navy to deliver mission-critical solutions that are grounded in science and engineering excellence and battlefield operational success,” said Barbara Supplee, SAIC Executive Vice President of the Army Navy Business Group. “This task order enables us to deliver best-in-class technologies that supports naval aviation at its core – AAE and SE sustainment – while driving revolutionary advancements for the MQ-25’s refueling capabilities.”

Supplee added, “Our teams don’t just deliver; we innovate, transform, and ensure the Navy retains the operational edge required to win tomorrow’s fight. This partnership, built on trust and proven performance, positions SAIC as the unparalleled choice for ensuring mission success across the Navy and the joint force.”

The task order supports key NAVAIR program offices such as PMA-201, responsible for common AAE; PMA-260, overseeing SE sustainment; and PMA-268, advancing ARS for the MQ-25. Managed platforms include the F/A-18 Hornet, P-8A Poseidon, SH-60 Seahawk, and MQ-25 Stingray, among others.

SAIC was awarded this contract for the company’s digital engineering tools, predictive analytics expertise, and proven relationship with the Navy. Over the past two decades, SAIC has delivered critical and innovative capabilities to sustain mission readiness and operational effectiveness for key Department of War customers. By prioritizing AAE and SE, while advancing the Navy’s MQ-25 refueling program, SAIC remains a trusted partner for driving superior performance and outcomes in the dynamic defense environment.

About SAIC 

SAIC® is a premier Fortune 500 mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end solutions in mission IT, enterprise IT, engineering services, and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.

We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.3 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.

Media Contact: 

Darryn James
[email protected]

Forward-Looking Statements 

Forward-Looking Statements Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at saic.com or on the SEC’s website at sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.